Oncology for the Inquisitive Mind

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT...

For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer. Studies: DeLLphi-303 SOHO-01 ALBATROS PAULIEN DREAM3R OptiTROP-Lung04...

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world. Studies...

After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the...

In this episode, the focus shifts away from the more "garden-variety" non-small cell lung cancer and to its less common, frequently more aggressive sibling, small cell lung cancer. Here, Josh and Michael examine the...

On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation...

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that...

Advanced or Metastatic Non Small Cell Lung Cancer (mNSCLCa), is one of the most common causes of death worldwide. This week, Michael provides an excellent background on this type of cancer, and Josh provides an...

To Josh's immense displeasure, our series on genitourinary cancer is done. For now, at least. In this episode, Michael and Josh step into the heavy shadow of non-small cell lung cancer, the most common cause of cancer...

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately...

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume multi-disciplinary...

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less common cluster of...

How do you increase access to phase 1 trials for a state with a population of 8 million people spread across 800,000 km^2? You collaborate! In this context, we explore NECTA. The New South Wales Early Phase Clinical...

Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal disease, with a...

Continuing on their Back to Basics GU extravaganza, Josh and Michael progress to the subject of kidney cancer, and bring you the answer to a question long unanswered: is there any benefit of adjuvant therapy in resected...

Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant management of urothelial...

In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Starting with the...

In this episode, Michael goes it alone, welcoming an old friend of the show, Dr Belinda Yeo, to discuss highlights in early breast cancer from ASCO 2025. The pair discuss an exciting new medication to assist with...

Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael...

Today, we discuss the latest advancements in gynecological oncology presented at ASCO 2025, featuring insights from Dr. Prachi Bhave. The conversation covers significant trials including the TRUST trial on ovarian...

In this episode, Dr. Janet Abrahm shares transformative insights from ASCO 2025, focusing on palliative care and supportive care in oncology. Topics discussed include the role of exercise in cancer survival, cannabis...

In this episode, Dr. Ned McNamee discusses the latest advancements in lung cancer treatment presented at ASCO 2025, focusing on significant studies such as the Phase 3 DeLLphi-304 study and Checkmate 816. They explore...

Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins...

Today, we’re joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent’s Hospital, Sydney, and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses multiple...

In this episode, we unpack game-changing insights from ASCO 2025 with a spotlight on breast cancer. Joining us is Dr. Adam Brufsky, a trailblazing oncologist and professor at the University of Pittsburgh, with 30 years...